« Back
Home /
RapaLink-1

RapaLink-1

Item no.	HY-111373-25mg
Manufacturer	MedChem Express
CASRN	1887095-82-0
Amount	25 mg
Quantity options	10 mM/1 mL 10 mg 1 mg 25 mg 5 mg
Category	Cell Biology Cell Status Necrosis Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.92
Citations	[1]Fan Q, et al. A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma. Cancer Cell. 2017 Mar 13;31(3):424-435.\|[2]Kuroshima K, et al. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against SU 11248-resistant renal cell carcinoma. Cancer Sci. 2020 May;111(5):1607-1618.\|[3]Mu F, et al. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy both in vivo and vitro. Biochem Biophys Res Commun. 2020 Apr 30;525(2):384-391.\|[4]Rodrik-Outmezguine VS, et al. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature. 2016 Jun 9;534(7606):272-6.
Smiles	NC1=C(C2=NC=N1)C(C3=CC=C(O4)C(N=C4N)=C3)=NN2CCCCNC(CCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N5)C=C5COCCO[C@H](CC[C@H]6C[C@H]([C@@](CC([C@@H](/C=C([C@H]([C@H](C([C@@H](C[C@@H]7C)C)=O)OC)O)\C)C)=O)([H])OC([C@@](CCCC8)([H])N8C(C([C@@]9(O[C@@](C[C@@H](/C(C)=C/C=C/C=C/7)OC)([H])CC[C@H]9C)O)=O)=O)=O)C)[C@@H](C6)OC)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1887095-82-0
Similar products	1887095-82-0
Shipping Condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Autophagy; mTOR
Shipping Temperature	Blue Ice
Storage Conditions	-20°C (Powder, sealed storage, away from moisture)
Molecular Weight	1784.14
Product Description	RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin (HY-10219) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity[1][2].
Manufacturer - Research Area	Cancer
Solubility	DMSO: ≥ 100 mg/mL\|H2O: < 0.1 mg/mL
Manufacturer - Pathway	Autophagy; PI3K/Akt/mTOR
Isoform	mTOR
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-111373-25mg-safety-datasheet.pdf